Pfizer boss Ian Read flies in to put AstraZeneca takeover case to MPs
The pharmaceutical giant's chairman and chief executive, and his AstraZeneca counterpart, will appear before the Commons Business Committee this week
Sunday 11 May 2014
The chief executive of US pharmaceutical giant Pfizer will arrive in the UK tomorrow to persuade the Government that its £60bn-plus hostile takeover of British rival AstraZeneca should be allowed.
Concern has been raised that what would be the biggest ever corporate takeover in the UK could result in the loss of thousands of skilled jobs and damage British research. The Government can block such deals in exceptional circumstances if the public interest is at risk, although lawyers have said intervention in this case is unlikely to comply with European trade laws.
Pfizer's chairman and chief executive, Ian Read, and his AstraZeneca counterpart, Pascal Soriot, will appear before the Commons Business Committee on Tuesday and the Science and Technology Committee the next day. The science committee will also question Science Minister David Willetts.
While Pfizer has given assurances that it would keep at least 20 per cent of the combined companies' research and development workforce in the UK for at least five years and base its European headquarters in Britain, David Cameron has said he is "not satisfied".
Mr Read said in a video on the company website: "I see this as a win-win for society, a win-win for shareholders, and a win-win for stakeholders."
He also said the deal would "liberate the balance sheet and tax" of both companies.
The Chancellor George Osborne, said yesterday he would make sure Pfizer executives gave "real promises that we can hold them to".
"I'm also prepared to get in the room and have a hard negotiation with very large companies and be very, very hard-nosed about what we want to deliver in terms of good British science and good British jobs," he told Radio 4's Today programme.
Shadow Business Secretary, Chuka Umunna, has written to Business Secretary Vince Cable saying there is "wide concern … across the business and science communities about the deal". "The assurances Pfizer has given are not worth the paper they are written on, given that Pfizer has since refused to rule out breaking up AstraZeneca and selling off parts of it in the future," he said.
- 1 This 'woman calls police to order pizza' story isn't going where you're expecting
- 2 Axe wielding man shot dead after attacking four New York policemen on busy street
- 3 Watch what happened when food critics were unknowingly served McDonald's
- 4 Jimmy Carr's Oscar Pistorius joke goes a bit too far at the Q Awards
- 5 Ottawa shootings: Bruce MacKinnon's cartoon is the perfect tribute to soldier Nathan Cirillo
Of course, teenage girls need role models – but not like beauty vlogger Zoella
Cameron is warned 'no possibility' of UK reducing immigration and that bid to bring in quota on migrant workers would be illegal
Support for EU membership 'at highest level since 1991' with most Brits wanting to stay 'in'
Thousands with degenerative conditions classified as 'fit to work in future' – despite no possibility of improvement
Attacks on 'Ukip Calypso' show how skewed people’s priorities are
Poppy Appeal 2014: This is why I won't be wearing a red poppy this year
iJobs Money & Business
£60000 per annum: Ashdown Group: Compensation and Benefits Manager - Compensat...
£30000 - £35000 Per Annum plus excellent benefits: Clearwater People Solutions...
£24000 - £28000 per annum + bonus & benefits: Ashdown Group: IT Business Syste...
£50000 - £90000 per annum + benefits: Ampersand Consulting LLP: Markit EDM (CA...